Assertio (ASRT) Reports Q4 Loss, Tops Revenue Estimates

Stock Information for Nektar Therapeutics

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Nektar Therapeutics

Assertio to Participate in the iAccess Alpha Virtual Best Ideas Conference on March 25-26, 2025
Assertio Reports Fourth Quarter and Full Year 2024 Financial Results
Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025
INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Assertio Holdings, Inc. (NASDAQ: ASRT); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors
Assertio Announces Results of Rolvedon® (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study
Assertio Holdings, Inc. Appoints Paul Schwichtenberg to New CTO Role, Mary Pietryga as CCO

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.